- Home
- MGN vs KALA Comparison
MGN vs KALA Comparison
Compare MGN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGN | KALA |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 3.7M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MGN | KALA |
|---|---|---|
| Price | $2.13 | $0.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 123.4K | ★ 499.1K |
| Earning Date | 11-29-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.07 |
| 52 Week High | $5.18 | $191.00 |
Technical Indicators
Market Signals| Indicator | MGN | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 23.48 |
| Support Level | $0.11 | $0.11 |
| Resistance Level | $2.19 | $0.61 |
| Average True Range (ATR) | 0.36 | 0.04 |
| MACD | -0.26 | -0.00 |
| Stochastic Oscillator | 7.58 | 28.49 |
Price Performance
Historical ComparisonAbout MGN Megan Holdings Limited Ordinary Shares
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.
About KALA KALA BIO Inc.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.